Clinical trials: Bipolar II Depression
Bipolar II Disorder
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included…
- Trial name
- NCT05839509
- Testing
- GH001
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 6 people
- Sponsor
- GH Research Ireland Limited
Bipolar II Disorder, Major Depressive Episode
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
- Trial name
- NCT00237666
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medical Research Network
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bipolar Disorder II, Major Depressive Disorder (MDD)
Type D Personality and Life Satisfaction in Bipolar Disorder Type 2 and Major Depressive Disorder
Bipolar Disorder Type II (BD-II) and Major Depressive Disorder (MDD) are common mood disorders associated with substantial psychological distress, impaired functioning, and reduced quality of life.
- Trial name
- NCT07679204
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Elazığ Mental Health and Diseases Hospital
Bipolar Disorder I, Bipolar II Disorder
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking…
- Conditions
- Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder
- Trial name
- NCT05705063
- Testing
- LCHF Ketogenic Diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Bipolar I or II Depression and Alcohol Abuse or Dependence
Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence
The purpose of this study is to determine if Divalproex Sodium can be used to Treat and Prevent Depression in Patients with Bipolar Disorder who have Comorbid Alcohol Dependence/Abuse.
- Trial name
- NCT00204503
- Testing
- Depakote ER
- Where
- United States
- Sponsor
- The University of Texas Medical Branch, Galveston
Bipolar Disorder
Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Double-Blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression Previously Diagnosed and Treated as Recurrent Major Depression: This study recruits males and females aged 18 - 70 who currently meet…
- Trial name
- NCT00194116
- Testing
- Divalproex Sodium ER
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Major Depressive Disorder, Bipolar I and Bipolar II
Bipolar Proteomic Assay Validation Study
The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
- Trial name
- NCT02746367
- Testing
- Diagnostic test (LDT)
- Where
- 5 sites in United States
- Volunteers
- 261 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Postpartum Depression
Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II
This is a 9-week single-centre, open-label, dose-escalating study evaluating the efficacy and safety of Quetiapine XR given as monotherapy in the treatment of non-lactating, post-partum women diagnosed with Bipolar II Disorder.
- Trial name
- NCT01527448
- Testing
- Quetiapine XR (seroquel)
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- BC Women's Hospital & Health Centre
Schizophrenia, Schizoaffective Disorder
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizotypal Disorder, Acute and Transient Psychotic Disorder
- Trial name
- SUCCEED (NCT06007105)
- Testing
- SUCCEED Community-Based Intervention
- Where
- 4 sites in Malawi, Nigeria and 2 more
- Volunteers
- 425 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Bipolar Disorder
Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded…
- Trial name
- NCT00109577
- Testing
- MCN36 (nutritional supplement)
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Depressive Disorder
The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression
The purpose of this study is to assess whether the antidepressant effect from intravenous (IV) ketamine treatment can be maintained by minocycline compared to placebo after IV ketamine treatment is stopped.
- Trial name
- NCT01809340
- Testing
- Minocycline, Ketamine
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.
- Trial name
- NCT00363337
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Lindner Center of HOPE
Bipolar Disorder
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00771134
- Testing
- Lu AA39959, Quetiapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder, Depression
Bipolar II Depression: Lithium, SSRI, or the Combination
This study will compare the safety and effectiveness of a mood stabilizing medication, an antidepressant medication, and a combination of both medications to treat symptoms of bipolar type II depression.
- Trial name
- NCT00276965
- Testing
- Sertraline, Lithium carbonate
- Where
- 3 sites in United States
- Volunteers
- 139 people
- Sponsor
- Lindner Center of HOPE
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-100 in Bipolar Disorder With Depression (BD-D)
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used…
- Trial name
- NCT06656416
- Testing
- ALTO-100
- Where
- 68 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alto Neuroscience
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
- Trial name
- NCT04433845
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sheppard Pratt Health System
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Depression
Vortioxetine Adjunctive Treatment in Bipolar Depression
Depressive episode of bipolar disorder is often the first symptom of patients with bipolar disorder, which is characterized by frequent recurrence, relatively long duration, high comorbidity rate and high fatality rate.
- Trial name
- Vortioxetine (NCT05481957)
- Testing
- Vortioxetine, valprote
- Where
- China
- Volunteers
- 131 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Bipolar Disorder I or II
Tranylcypromine Treatment of Bipolar Depression
This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in…
- Trial name
- NCT01430455
- Testing
- Tranylcypromine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- New York State Psychiatric Institute